eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » Recommendations for User Fee Programs: Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 Through 2017; Meeting

Recommendations for User Fee Programs: Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 Through 2017; Meeting

Document ID: FDA-2011-N-0326-0024
Document Type: Notice
Agency: Food And Drug Administration
Topics: No Topics associated with this document
Federal Register Number: 2011-31499
View Document:  View as format pdf View as format html

Details Information

Abstract: Meeting on 12/16/2011
Document Subtype: Notice of Public Meeting
Received Date: December 06 2011, at 12:00 AM Eastern Standard Time
Start-End Page: 76424 - 76429
Page Count: 6
Comment Start Date: December 7 2011, at 12:00 AM Eastern Standard Time
Comment Due Date: January 6 2012, at 11:59 PM Eastern Standard Time

Comments

    View All
Total: 12
Academy of Managed Care Pharmacy (AMCP) - Comment
Posted: 01/11/2012     ID: FDA-2011-N-0326-0026

Jan 06,2012 11:59 PM ET
Shein-Chung Chow, PhD Duke University School of Medicine - Testimony
Posted: 01/11/2012     ID: FDA-2011-N-0326-0027

Jan 06,2012 11:59 PM ET
BIO - Testimony
Posted: 01/11/2012     ID: FDA-2011-N-0326-0028

Jan 06,2012 11:59 PM ET
Pfizer Inc - Comment
Posted: 01/11/2012     ID: FDA-2011-N-0326-0032

Jan 06,2012 11:59 PM ET
AARP - Comment
Posted: 01/11/2012     ID: FDA-2011-N-0326-0034

Jan 06,2012 11:59 PM ET

Related Documents

Total: 0
No documents available.